Abstract Objectives: To develop and optimize a thermoreversible in-situ nasal gel of Zavegepant for effective and rapid treatment of acute migraine, enhancing brain targeting and bioavailability while overcoming limitations of oral formulations. Methods: A 3² full factorial design was employed to evaluate the effects of Pluronic F-127 (X₁) and xanthan gum (X₂) on gelation temperature (Y₁) and mucoadhesive strength (Y₂). Nine formulations (VF1–VF9) were developed and evaluated for physicochemical properties, gelation behavior, mucoadhesion, in-vitro drug release, ex vivo permeation, and in vivo anti-migraine efficacy using a nitroglycerin-induced migraine model in rats. Results: Optimized batch VF2 containing 20% Pluronic F-127 and 0.2% xanthan gum showed a gelation temperature of 34.94 °C and mucoadhesive strength of 5812.2 dyne/cm² with minimal prediction error (Conclusion: The optimized thermosensitive nasal gel (VF2) of Zavegepant presents a promising, non-invasive strategy for acute migraine therapy with sustained drug release, enhanced mucosal retention, and effective CNS delivery. Its clinical potential lies in offering fast, localized treatment with fewer systemic side effects and improved patient compliance.
Pawar et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: